Senzime Ab · OMXSTO:SEZI
Senzime Ab — Q1 2025 Earnings Presentation
17 slides from Senzime Ab's earnings presentation, Apr 22, 2025
Slide 1: Q1 2025 Interim Report
Q1 2025 Interim Report Senzime AB (publ.) Jan – March 2025
Slide 2: Smarter anesthesia. Safer recoveries.
Smarter anesthesia. Safer recoveries.
Slide 3: Senzime leads a paradigm shift in patient safety by monitoring level of block
Senzime leads a paradigm shift in patient safety by accurately monitoring the patient’s level of block Algorithm-powered monitoring to secure precise dosing of paralytic drugs empowering clinicians with real-time signals to confidently determine when it's safe for patients to breathe on their own. 3
Slide 4: Q1 2025: 94% sales growth
Q1 2025: 94% sales growth Net sales increased to SEK 23.5 million (12.1) Q1 2025 revenues (MSEK) 1 corresponding to 94% growth rate, boosted by Next- gen TetraGraph and TetraSens sales. Strong growth in 25 all major markets incl key new hospital wins. Deliveries of disposable sensors grew 115% drive
Slide 5: One of the fastest growing medical device companies on Nasdaq Stockholm
We continue to be one of the fastest growing medical device company on Nasdaq Stockholm Net sales rolling 12-months (kSEK) Net sales per quarter (kSEK) 70,000 25,000 65,000 60,000 55,000 20,000 50,000 45,000 15,000 40,000 35,000 30,000 10,000 25,000 20,000 15,000 5,000 10,000 5,000 0 0 Q1 Q2 Q3 Q4 Q
Slide 6: Installed base of TetraGraph monitors keeps growing, driving disposable sensor sales
Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors Total delivered base of TetraGraph-systems Shipped disposable sensors (units) by month ‘22 - March ‘25 3,500 35,000 3,500 3,000 TetraGraphs 30,000 283 990 (129 700) delivered to TetraSens sensors sold date l
Slide 7: Q1 2025 - Strong growth in all markets
Q1 2025 - Strong growth in all markets Currency Reported adjusted Net Sales by product group (Q125) Net Sales by region (Q125) Q1, KSEK 2025 Q1 2024 Q1 Growth Growth Europe US 15 551 9 037 72% 68% 16% Devices/other 6 288 3 770 67% 64% Devices/ Disposables 9 262 5 267 76% 71% other Europe 3 816 1 447
Slide 8: Very strong market reception of the new next-generation TetraGraph
Very strong market reception of the new next-generation TetraGraph Now also launched in Europe TetraGraph® Adaptive 6th Generation Intelligence EMG Algorithm Aids in signal strength optimization and automates workflows with Analyzes muscle function TetraGraph® Adaptive PTC and at 4 times higher reso
Slide 9: Key hospital and contract wins Q1 2025
Key hospital and contract wins Q1 2025 IDN Northeastern US for initial delivery of 60 next-generation TetraGraphs. Won University hospital following a competitive evaluation including EMG and legacy Mountain region AMG technologies, The contract represents an opportunity for recurring sensor revenue
Slide 10: Continuing to secure our leading market positioning
Continuing to secure our leading market positioning Increased production Further expansion of US Winning by Science – capacity in Uppsala to commercial team to meet formation of new Medical meet global demands market demands Affairs team Production team expanded in Uppsala US sales team expansion to
Slide 11: Leading and educating the industry
Leading and educating the industry Senzime Academy 10 Board of Directors Global Marketing Presentation | 18 March 2025 | Confidential, for Internal Use Only
Slide 12: Rapid sales growth combined with stable operating expenses
Rapid sales growth combined with stable operating expenses Quarterly Operating expenses (KSEK) 45,000 40,660 • OPEX of 37,297 kSEK (37,441) in-line with 40,000 37,441 37,297 previous year despite significant 34,266 investments in US commercial team and 35,000 global marketing to meet demand from 30,
Slide 13: Progression towards profitability
Progression towards profitability Quarterly EBITDA (KSEK) 0 • EBITDA improved 27% to -20,839 kSEK (-28,546) driven by higher sales, better -5,000 margin and lower OPEX. • 62 MSEK in cash end of Q1 plus additional -10,000 2.5 MSEK expected in Q2 2025 from directed shares issue in 2024. -15,000 • We h
Slide 14: Shareholding update, March 31st, 2025
Shareholding update, March 31st, 2025 Largest shareholders March 31, 2025 Dec 31, 2024 Diff vs Q1 2025 Sept 30, 2024 Diff vs Q1 2025 Crafoord family and the Crafoord Foundation 22 644 051 17,0% 22 644 051 17,0% 0 20 222 151 16,9% 2 421 900 Segulah Venture AB, Segulah AB, SMA 14 820 271 11,1% 14 820
Slide 15: US tariffs, comments based on current know-how
US tariffs, comments based on current know-how 1. With a high portion of sales in the US market, Senzime will as most industry peers be affected by the new tariffs. 2. Senzime has a strong local supply chain sourcing mainly from within EU, and these have further to some extent dependencies on Asian
Slide 16: Key take-aways
Key take-aways Senzime’s mission is to be the undisputed global market leader in the field of EMG-based quantitative neuromuscular monitoring. Backed by long- Pioneering state-of-the art Supported by recent Senzime’s commercial term science and technology driving a paradigm guidelines in US, EU, UK
Slide 17: Concluding remarks
Concluding remarks 1. Senzime’s growth journey continues in an inflection point market with strong market demand driven by the guidelines published in 2023. 2. Our technology is rapidly establishing itself as the new clinical standard in operating rooms of leading hospitals around the world. Next-ge